Intomics will assist Lundbeck with methods and tools for analysing and integrating large quantities of biological data generated in the drug development process.
Intomics CEO Thomas Jensen said that with their data-analysis capabilities and Lundbeck’s expertise in the central nervous system area, they see a great synergy that has the potential to benefit patients with central nervous system (CNS) related disorders.
Lundbeck conducts research into, developing, manufacturing, marketing, selling and distributing pharmaceuticals for the treatment of disorders in the CNS, including depression, schizophrenia, Alzheimer’s, Parkinson’s, Huntington’s, epilepsy and insomnia.